Be a part of a new era in cellular therapy for the potential treatment of solid-tumor cancers

Many advancements have been made in the treatment of cancer, including a recent focus to develop treatments that activate the immune system to fight cancer, called immunotherapies.

Despite this progress, existing immunotherapies are effective in a relatively small number of patients and types of cancer. Furthermore, in some cases even when therapies are initially effective, the disease eventually no longer responds to treatment and progresses. For the treatment of cancer, Rubius Therapeutics is creating engineered red blood cells with cancer-fighting proteins on the cells’ surface to mimic how the immune system naturally functions to fight cancer. These Red Cell Therapeutics™ have the potential to extend the benefits of immunotherapy to a larger number of patients and in more types of cancers.

Rubius Therapeutics is developing a potential new cancer treatment option, called RTX-224, for patients with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, urothelial (bladder) cancer, head and neck cancer and triple-negative breast cancer.

About RTX-224
RTX-224 is an investigational cellular therapy that aims to activate the immune system to fight cancer.

RTX-224 is an engineered red blood cell that is being evaluated in a Phase 1/2 clinical trial for the treatment of patients with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, urothelial (bladder) cancer, head and neck cancer and triple-negative breast cancer. RTX-224 is engineered to simultaneously present hundreds of thousands of copies of the costimulatory proteins 4-1BBL and IL-12 and is designed to stimulate innate and adaptive immunity by activating natural killer (NK) cells and T cells inside the patient’s body to generate an anti-tumor immune response.

Learn more about the RTX-224 clinical trial